ResultsIQ

ResultsIQ › Latest results › Aurobindo Pharma Limited

Aurobindo Pharma Limited Q2 FY27 earnings call summary

NSE: AUROPHARMA · BSE: 524804

Earnings call of 5 Nov 2026, summarised by AI from the filing.

Aurobindo reported highest ever quarterly revenue of ₹10,263 cr, up 24% year-on-year, and reiterated FY27 guidance of double-digit revenue growth and EBITDA margin north of 21%.

Key takeaways

  1. Revenue Highest ever quarterly revenue of ₹10,263 cr, up 24% year-on-year.
  2. Guidance FY27 guidance reiterated: double-digit revenue growth, EBITDA margin north of 21%, EBITDA above ₹8,000 cr.
  3. Lannett Lannett acquisition completed and integrated; management says it is close to Aurobindo's EBITDA standard.
  4. Respiratory gAdvair launched mid-quarter and generic QVAR approved; full benefit expected in coming quarters.
  5. Input costs Raw material procurement cost rose due to the Gulf issue; full impact not yet in consumption.

Original filing on BSE

Aurobindo Pharma Limited Q2 FY27 results

As filed: Revenue ₹10,263 cr (+24% year on year), EBITDA ₹2,156 cr (+29% year on year), PAT ₹1,124 cr (+33% year on year), EBITDA margin 21.0% (+77 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹9,150 cr (+16% year on year), EBITDA ₹1,881 cr (+17% year on year), PAT ₹1,032 cr (+25% year on year), EBITDA margin 20.6% (+17 bps). Score 70 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 17 bps year on year. Share price after the results: +2.5% in 30 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹8,853 cr (+6% year on year), EBITDA ₹1,753 cr (−2% year on year), PAT ₹921 cr (+2% year on year), EBITDA margin 19.8% (−157 bps). Score 33 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 157 bps year on year. Share price after the results: −3.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹8,646 cr (+8% year on year), EBITDA ₹1,773 cr (+12% year on year), PAT ₹910 cr (+8% year on year), EBITDA margin 20.5% (+73 bps). Score 40 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 73 bps year on year. Share price after the results: +8.4% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹8,286 cr (+6% year on year), EBITDA ₹1,677 cr (+7% year on year), PAT ₹848 cr (+4% year on year), EBITDA margin 20.2% (+15 bps). Score 33 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 15 bps year on year. Share price after the results: +6.0% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹7,868 cr (+4% year on year), EBITDA ₹1,604 cr (−1% year on year), PAT ₹824 cr (−10% year on year), EBITDA margin 20.4% (−101 bps). Score 20 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 101 bps year on year. Consolidated profit -10% but standalone +70%. Revenue fell 6% from last quarter. Revenue rose ₹301 cr on a year ago, against ₹716 cr the year before. Share price after the results: −5.1% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹8,382 cr (+11% year on year), EBITDA ₹1,791 cr (+7% year on year), PAT ₹903 cr (0% year on year), EBITDA margin 21.4% (−69 bps). Score 33 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 69 bps year on year. Share price after the results: −4.9% in 30 days (Nifty 500: +2.7%).
  • Q3 FY25: Revenue ₹7,979 cr (+9% year on year), EBITDA ₹1,578 cr (−1% year on year), PAT ₹846 cr (−10% year on year), EBITDA margin 19.8% (−200 bps). Score 19 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 200 bps year on year. Revenue rose ₹627 cr on a year ago, against ₹945 cr the year before.

Past price moves after results do not indicate future moves. Not a recommendation.

Aurobindo Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.